Portola Pharmaceuticals Inc. stock fell 7% in late trading Friday afternoon after the company said a regulatory review of a proposed drug would be extended. The Food and Drug Administration asked Portola for more data on a study of the biologic drug, AndexXa, which will extend the time allowed for the review by 90 days. Portola said that the review period will now end May 4, 2018, instead of Feb. 3. AndexXa is being developed as an antidote for anticoagulant drugs, which can lead to uncontrolled bleeding. Portola shares declined to about $51 in after-hours trading, after closing Friday at $54.86.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News